Core Insights - Silexion Therapeutics Corp. announced promising preclinical data for SIL-204, demonstrating significant tumor growth reduction in orthotopic pancreatic cancer models, validating systemic administration as an effective delivery method [1][2][5] Preclinical Data Highlights - SIL-204 reduced tumor growth by approximately 50% after 30 days, with around 50% of tumors showing complete necrosis in human pancreatic tumors with a G12D mutation xenografted into mice [7] - A single systemic administration of SIL-204 maintained effective drug levels in rat plasma and tissues for over 56 days [7] - SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D [7] - Intratumoral administration of SIL-204 microparticles reduced tumor cell numbers by approximately 3-fold and increased tumor necrosis by approximately 5-fold after 15 days in human pancreatic cancer xenograft harboring a KRAS G12V mutation in mice [7] Future Development Plans - The company is exploring how the new data can inform an expanded treatment strategy for KRAS-driven cancers and plans to announce details of its expanded development plan shortly [3]
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models